Kitalys Institute

Kitalys Institute's Targeting Health Longevity 2025 Session 1 - Draft Healthspan Legislation: the THRIVE Act, will be held Friday, February 28, 2025. To learn more about this initiative, go to https://lnkd.in/gm2mXAF7. To register for the webinar, go to https://lnkd.in/gWwGPrfG. Consider registering even if you are unable to attend as those registered will receive a complimentary video link and access to the THRIVE Act.

2025 TARGETING HEALTHY LONGEVITY (previously Targeing Metabesity) Conference Session 1: Draft Healthspan Legislation - the THRIVE Act Free webinar on Friday, February 28, 2025 from 11 a.m. to 12:30 p.m. ET Register here: https://lnkd.in/ez5pf3rW -- How would we know if a drug (or device or food or supplement) helped to slow the aging process? -- What evidence should be needed to approve a product to delay multiple chronic diseases of aging? -- What incentives (if any) are needed to promote investment in clinical data on extending healthspan? Accelerating advances in science suggest drugs, devices, and even foods and supplements may be able to delay, or even reverse, biological aging, and thereby delay chronic diseases, from diabetes to obesity to cardiovascular and neurodegenerative diseases to many kinds of cancer. However, a clear regulatory pathway for healthspan products has been among the biggest challenges to investment and their development. Drawing on precedents such as the 21st Century Cures Act and the Orphan Drug Act, the Kitalys Institute has proposed the draft THRIVE Act - the Therapeutic Healthspan, Research, Innovation and Enhancement Act - as a framework for regulatory pathways, fit-for-purpose evidence and incentives for healthspan products. All interested in developing healthspan products, and in the future of healthcare (not just sickcare), please consider joining us for this critical free webinar for the emerging trillion dollar healthy longevity industry. Part 1 will be a ‘fireside chat’ discussing the draft Act with Dr. Alexander Fleming, Founder and President of the Kitalys Institute (and former FDA official who led approvals of meformin and hte first statin, insulin analogue and growth hormone for non-GH deficiency conditions), and David Fox, Partner at Hogan Lovells (and former Associate Chief Counsel at FDA), moderated by Thomas Seoh, CEO of Kinexum. Part 2 will be a discussion of the draft Act by an eminent panel to be announced. Please register even if you have a conflict, to receive a link to the recording. #Healthcare #Healthspan #FDA #NIH #NIA #longevity #MAHA #A4LI #HSAC #AFAR #GSA

We’re pleased to make available the video recordings of “Novel Interventions for Preempting Neurodegeneration” - Session 2 of Targeting Healthy Longevity 2024, which took place on June 14. ?? Warmup Discussion with Jamie Justice, Joan Mannick, and George Vradenburg: https://bit.ly/3RvyH1i ?? Targeting Healthy Longevity 2024 Session 2: Novel Interventions for Preempting Neurodegeneration: https://bit.ly/4ctME7K All sessions can be viewed at www.healthy-longevity.org #neurodegeneration #dementia #Alzheimers #Parkinsons #healthspan #healthylongevity #healthyaging

Thank you! #collaboration #silobusting #solutions #neurodegeneration #Alzheimers #brainhealth #healthspan #Parkinsons #healthylongevity #healthyaging

??Top researchers at the intersection of neurodegeneration and healthy longevity will be gathering tomorrow, June 14, to discuss potential early-stage interventions to prevent dementia, Parkinson’s disease, and other neurodegenerative conditions – with an emphasis on interventions that could be used in people with very early or no disease (even young, healthy people). ??Register now (for free) for Session 2 of Targeting Healthy Longevity 2024: “Novel Interventions for Preempting Neurodegeneration”: bit.ly/44RTVvA ??From small molecules and vaccines to GLP-1 agonists already approved for other indications, the conversation will cover a multitude of related topics. Many of the approaches to be discussed will also reduce risks of other major chronic diseases. ??Lee Rubin, PhD, Professor of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute – along with Lawrence Steinman, MD, George A. Zimmerman Professor of Neurology and Neurological Sciences, and Pediatrics, Stanford University – will co-moderate. ??Expert panelists will include: ? David Holtzman, MD, Barbara Burton and Reuben M. Morriss III Distinguished Professor, Department of Neurology, Washington University School of Medicine ? Beth Stevens, PhD, Associate Professor Department of Neurology, Harvard Medical School ? Saul Villeda, PhD, Associate Professor, Department of Anatomy, University of California San Francisco ? Tony Wyss-Coray, PhD, D.H. Chen Distinguished Professor of Neurology and Neurological Sciences, Stanford University ?? A pre-session chat to kick off the day’s event will feature: ? Jamie Justice, PhD, Executive Vice President of the Health Domain at XPRIZE, an established global leader in designing, launching, and executing large-scale competitions to solve humanity’s greatest challenges ? Joan Mannick, MD, Co-founder and CEO at Tornado Therapeutics, a biotech company developing safer, more effective rapalogs to treat disease and extend healthy lifespan ? George Vradenburg, Founder and Chairman of UsAgainstAlzheimer's, a nonprofit established in 2010 to disrupt and diversify the movement to cure Alzheimer’s #Alzheimers #Parkinsons #neurodegeneration #healthspan #healthyaging George Vradenburg UsAgainstAlzheimer's Joan Mannick Jamie Justice, Ph.D. XPRIZE

?? Just two more days! Register now for Session 2 of Targeting Healthy Longevity 2024: “Novel Interventions for Preempting Neurodegeneration” ?? Friday, June 14, from 1:30-3:30 p.m. EDT ?? To register, visit: bit.ly/44RTVvA ?? This important conversation among some of the very top researchers at the intersection of neurodegeneration and healthy longevity will cover potential early-stage interventions to prevent dementia, Parkinson’s disease, and other neurodegenerative conditions, with an emphasis on interventions that could be used in people with very early or no disease (even young, healthy people). ?? From small molecules and vaccines to GLP-1 agonists already approved for other indications, the conversation will cover a multitude of related topics. Many of the approaches to be discussed will also reduce risks of other major chronic diseases. ?? Lee Rubin, PhD, Professor of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute – along with Lawrence Steinman, MD, George A. Zimmerman Professor of Neurology and Neurological Sciences, and Pediatrics, Stanford University – will co-moderate. ?? Expert panelists will include: ? David Holtzman, MD, Barbara Burton and Reuben M. Morriss III Distinguished Professor, Department of Neurology, Washington University School of Medicine ? Beth Stevens, PhD, Associate Professor Department of Neurology, Harvard Medical School ? Saul Villeda, PhD, Associate Professor, Department of Anatomy, University of California San Francisco ? Tony Wyss-Coray, PhD, D.H. Chen Distinguished Professor of Neurology and Neurological Sciences, Stanford University ?? A pre-session chat to kick off the day’s event will feature: ? Jamie Justice, PhD, Executive Vice President of the Health Domain at XPRIZE, an established global leader in designing, launching, and executing large-scale competitions to solve humanity’s greatest challenges ? Joan Mannick, MD, Co-founder and CEO at Tornado Therapeutics, a biotech company developing safer, more effective rapalogs to treat disease and extend healthy lifespan ? George Vradenburg, Founder and Chairman of UsAgainstAlzheimer's, a nonprofit established in 2010 to disrupt and diversify the movement to cure Alzheimer’s #neurodegeneration #healthspan #aging #longevity

??We invite you to join us for Session 2 of Targeting Healthy Longevity 2024: “Novel Interventions for Preempting Neurodegeneration,” to take place on Friday, June 14, from 1:30 to 3:30 p.m. EDT. ??Registration is free of charge and is required in order to attend: bit.ly/44RTVvA ??Lee Rubin, PhD, Professor of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute – along with Lawrence Steinman, MD, George A. Zimmerman Professor of Neurology and Neurological Sciences, and Pediatrics, Stanford University – will co-moderate Session 2. ??With a panel of leading researchers, they will discuss potential early-stage interventions to prevent dementia, Parkinson’s disease, and other neurodegenerative conditions, with an emphasis on interventions that could be used in people with very early or no disease – even young, healthy people. ??From small molecules and vaccines to GLP-1 agonists already approved for other indications, the conversation will cover a multitude of related topics. Many of the approaches to be discussed will also reduce risks of other major chronic diseases.

?? Join us for this important conversation on Friday, June 14, at 1:30 p.m. EDT for Session 2 of Targeting Healthy Longevity 2024: “Novel Interventions for Preempting Neurodegeneration.” ?? The session is free and open to all. ?? Register now: bit.ly/44RTVvA #Alzheimers #Parkinsons #dementia #brainhealth #aging #healthspan #longevity UsAgainstAlzheimer's XPRIZE Tornado Therapeutics ?

Targeting Healthy Longevity 2024 free virtual Session 2 announced for June 14, 2024 with an all-star cast on novel interventions for preempting neurodegeneration! #longevity #metabesity #aging #neurodegeneration #Alzheimers #Parkinsons #kitalys

We appreciate this insightful breakdown of the state of aging in America by Caitlin Owens at Axios. She takes a look at efforts to target aging itself—and includes the perspective of the Kitalys Institute’s founder and president Dr. Alexander Fleming (also executive chairman of Kinexum): ? “The big picture: ‘The distinction here is we're looking for approaches that are going to reduce the risk of all the major chronic diseases by targeting shared root causes,’ said Alexander Fleming, executive chairman of consultancy Kinexum and a former FDA official who oversaw approvals of drugs for diabetes and other metabolic diseases. ·?‘We are interested in actually intervening much earlier — in people your age and younger — to reduce your risk of getting these diseases.’ (I am 31, for the record.)” https://lnkd.in/eNz_6Td5 #aging #healthspan #longevity